A quiet cardio upstart makes some noise, getting $300M from Bain and diving deep into the clinic — with some real money for pipeline deals
The small executive team at Cardurion has been sticking carefully to its goals, in-licensing a lead cardio drug from Astellas in 2018 and making a careful trek into human studies as they advanced a follow-up program and gradually built out another preclinical prospect.
Involved in one of the most grindingly tough fields in drug R&D, they never thought much of touting their work. They did deals with Takeda and Pfizer without making much of a show of it. Even established a small operating unit in Japan. Polaris invested, but no one ever said how much — or much about why.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.